Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 10,320
-80 (-0.77%)
Apr 4, 2025, 3:30 PM KST
Hyundai Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -6,930 | -14,499 | -15,807 | -20,051 | -8,260 | Upgrade
|
Depreciation & Amortization | 633.82 | 1,435 | 1,782 | 2,703 | 3,778 | Upgrade
|
Asset Writedown & Restructuring Costs | - | 4,769 | - | 7,517 | 2,829 | Upgrade
|
Loss (Gain) From Sale of Investments | -14.05 | -123.67 | -910.99 | - | - | Upgrade
|
Loss (Gain) on Equity Investments | 5,730 | - | -8,834 | -93.91 | -1,542 | Upgrade
|
Stock-Based Compensation | -77.98 | 402.42 | 596.94 | 578.26 | 1,032 | Upgrade
|
Provision & Write-off of Bad Debts | 156.13 | -28.78 | 5,260 | -583.99 | -212.84 | Upgrade
|
Other Operating Activities | 2,579 | 911.44 | -79.49 | 3,925 | 2,170 | Upgrade
|
Change in Accounts Receivable | 43.52 | 864.23 | 1,184 | 3,526 | 4,585 | Upgrade
|
Change in Inventory | 1,512 | 358.12 | 403.6 | 864.9 | 1,865 | Upgrade
|
Change in Accounts Payable | 447.9 | -256.2 | 503.57 | 13.43 | 1,355 | Upgrade
|
Change in Other Net Operating Assets | -1,824 | 159.77 | -642.06 | 1,063 | -97.7 | Upgrade
|
Operating Cash Flow | 2,257 | -6,008 | -16,544 | -538.48 | 7,502 | Upgrade
|
Operating Cash Flow Growth | - | - | - | - | -18.27% | Upgrade
|
Capital Expenditures | -169.57 | -539.7 | -1,544 | -3,747 | -25,204 | Upgrade
|
Sale (Purchase) of Intangibles | -2,000 | -47.84 | - | -15.12 | - | Upgrade
|
Investment in Securities | -16,934 | 6,000 | 10,210 | -13,010 | 941.66 | Upgrade
|
Other Investing Activities | -773.14 | -557 | -0.4 | 1,773 | 2.43 | Upgrade
|
Investing Cash Flow | -19,740 | 5,177 | 8,518 | -12,359 | -26,831 | Upgrade
|
Short-Term Debt Issued | - | - | - | - | 2,000 | Upgrade
|
Long-Term Debt Issued | 20,001 | - | - | - | 33,000 | Upgrade
|
Total Debt Issued | 20,001 | - | - | - | 35,000 | Upgrade
|
Short-Term Debt Repaid | -400 | -500 | -500 | - | - | Upgrade
|
Long-Term Debt Repaid | -116.58 | -362.88 | -1,194 | -1,246 | -1,182 | Upgrade
|
Total Debt Repaid | -516.58 | -862.88 | -1,694 | -1,246 | -1,182 | Upgrade
|
Net Debt Issued (Repaid) | 19,484 | -862.88 | -1,694 | -1,246 | 33,818 | Upgrade
|
Issuance of Common Stock | 139.96 | 1,094 | 3,596 | 4,449 | - | Upgrade
|
Other Financing Activities | -434.78 | -289.18 | -229.04 | -209.66 | -867.11 | Upgrade
|
Financing Cash Flow | 19,190 | -57.97 | 1,673 | 2,994 | 32,951 | Upgrade
|
Foreign Exchange Rate Adjustments | 138.47 | -31.72 | -103.42 | -122.29 | 37.95 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0 | - | - | - | -0 | Upgrade
|
Net Cash Flow | 1,845 | -920.54 | -6,456 | -10,026 | 13,660 | Upgrade
|
Free Cash Flow | 2,087 | -6,548 | -18,087 | -4,285 | -17,702 | Upgrade
|
Free Cash Flow Margin | 13.87% | -69.06% | -230.36% | -46.37% | -141.49% | Upgrade
|
Free Cash Flow Per Share | 52.42 | -164.84 | -459.44 | -116.08 | -492.91 | Upgrade
|
Cash Interest Paid | 434.78 | 289.18 | 222.4 | 209.66 | 259.11 | Upgrade
|
Cash Income Tax Paid | -54.28 | 19.19 | -17.99 | 78.92 | -15.64 | Upgrade
|
Levered Free Cash Flow | -2,607 | -4,900 | -8,388 | 1,337 | -21,504 | Upgrade
|
Unlevered Free Cash Flow | -1,162 | -4,704 | -8,108 | 3,214 | -20,797 | Upgrade
|
Change in Net Working Capital | 21.39 | -576.35 | -8,098 | -10,079 | -3,398 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.